Priapism

Disclaimer: This clinical reference is intended for informational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Clinicians must exercise their independent judgment and consider individual patient circumstances, available evidence, and current guidelines when making patient care decisions.

Overview

• Definition: Priapism is a persistent penile erection lasting more than four hours that is unrelated to sexual stimulation and unrelieved by ejaculation. It is a urological emergency, particularly the ischemic type, requiring prompt intervention to prevent long-term erectile dysfunction (ED).
• Epidemiology:
  • Incidence: Approximately 1.5 cases per 100,000 person-years in the general population, but significantly higher in specific groups (e.g., 29-42% lifetime risk in adult males with sickle cell disease).
  • Demographics: Can occur at any age, with bimodal peaks in incidence: children aged 5-10 years (often associated with sickle cell disease) and adults aged 20-50 years.
  • Types: Ischemic priapism accounts for the vast majority (approximately 95%) of cases.
• Classification:
  1. Ischemic (Veno-occlusive, Low-Flow) Priapism: The most common and urgent form. Characterized by impaired venous outflow from the corpora cavernosa, leading to progressive hypoxia, acidosis, and cellular damage. The penis is typically fully rigid and painful.
  2. Non-Ischemic (Arterial, High-Flow) Priapism: Characterized by unregulated arterial inflow into the corpora cavernosa, usually due to a fistula between a cavernosal artery and the lacunar spaces, often following perineal or penile trauma. The erection is typically less rigid, not fully engorged, and usually painless.
  3. Recurrent (Stuttering) Priapism: A subtype of ischemic priapism involving recurrent episodes of prolonged, painful erections that spontaneously resolve. Often a precursor to full-blown ischemic priapism and most commonly associated with sickle cell disease.

Pathophysiology

• Mechanism:
  • Ischemic Priapism: Failure of the normal detumescence mechanism. The smooth muscle cells within the corpora cavernosa remain contracted, trapping deoxygenated blood. This leads to impaired venous drainage, causing intracavernosal blood to become progressively deoxygenated, acidotic, and hypercarbic. Prolonged ischemia (>4-6 hours) can lead to smooth muscle necrosis, fibrosis, and damage to the cavernosal nerve, ultimately resulting in erectile dysfunction. The exact triggers often involve dysregulation of nitric oxide (NO) and phosphodiesterase-5 (PDE5) pathways, endothelin-1, or adenosine.
  • Non-Ischemic Priapism: Typically results from uncontrolled arterial inflow due to a laceration or rupture of a cavernosal artery or its branches, creating an arteriovenous fistula. This allows arterial blood to continuously fill the lacunar spaces without adequate detumescence. The blood is well-oxygenated, preventing ischemia.
• Risk Factors:
  • Hematologic Disorders:
    • Sickle cell disease (most common cause in children and a significant cause in adults)
    • Thalassemia
    • G6PD deficiency
    • Leukemia (especially chronic myeloid leukemia), multiple myeloma
    • Fabry disease
  • Pharmacologic Agents (Drug-Induced):
    • Intracavernosal vasoactive injections: Alprostadil (PGE1), papaverine, phentolamine (used for ED treatment)
    • Antidepressants: Trazodone (most commonly implicated), bupropion, sertraline, fluoxetine
    • Alpha-adrenergic antagonists: Prazosin, terazosin, doxazosin, tamsulosin (used for hypertension or BPH)
    • Antihypertensives: Hydralazine, guanethidine
    • Anticoagulants: Warfarin, heparin (rarely)
    • Recreational drugs: Cocaine, marijuana, ecstasy, gamma-hydroxybutyrate (GHB)
    • Erectile dysfunction medications: Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil, avanafil), especially when combined with other risk factors or in susceptible individuals.
    • Antipsychotics: Risperidone, olanzapine, clozapine
  • Neurological Conditions:
    • Spinal cord injury
    • Cauda equina syndrome
    • Autonomic neuropathy
  • Trauma: Perineal or penile trauma (leading cause of non-ischemic priapism).
  • Neoplasms: Primary or metastatic penile cancer, prostate cancer (rarely).
  • Total Parenteral Nutrition (TPN): Rarely reported.
• Protective Factors: Not well-defined for preventing the initial occurrence. For recurrent priapism, adherence to prophylactic medical therapy can reduce episodes.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Ischemic Priapism:
    • Persistent erection >4 hours.
    • Painful erection (often severe, progressive).
    • Rigidity of the corpora cavernosa (penile shaft is firm), but the glans penis and corpus spongiosum (where the urethra lies) are typically flaccid/soft.
    • No sexual interest or stimulation preceding the event.
  • Non-Ischemic Priapism:
    • Persistent erection >4 hours.
    • Less painful or painless erection.
    • Less rigid than ischemic priapism (penis may be partially tumescent or spongy, often described as "not fully hard").
    • History of recent perineal or penile trauma (e.g., straddle injury, direct blow) often preceding the erection by hours to days.
• Early Signs: Prolonged erection after sexual activity or medication, which persists despite detumescence efforts.
• Advanced Signs: In ischemic priapism, if left untreated, the penis may become edematous, discolored, and ultimately necrotic. Irreversible corporal smooth muscle damage.
• Atypical Presentations:
  • Stuttering Priapism: Recurrent, self-limiting episodes of painful erections that resolve spontaneously, often lasting 1-3 hours. Can be mistaken for normal erections or nocturnal tumescence if not specifically questioned.
  • Neonatal priapism: Very rare, sometimes associated with polycythemia or hyperviscosity.

Physical Examination

• Inspection:
  • Ischemic: Penile shaft appears engorged, rigid, often discolored (darker hue) in prolonged cases. Glans penis typically remains soft and non-engorged.
  • Non-Ischemic: Penile shaft is tumescent but often less rigid than in ischemic priapism. Glans penis may or may not be engorged. May observe signs of trauma (bruising, ecchymosis) on the perineum or penis.
• Palpation:
  • Ischemic: Corpora cavernosa are turgid and non-compressible, resembling a stone-hard erection. Glans penis is soft. Tenderness on palpation.
  • Non-Ischemic: Corpora cavernosa are tumescent but often partially compressible. Less tenderness.
• Special Tests: None specific for priapism on physical exam beyond careful inspection and palpation. The critical diagnostic differentiation relies on intracavernosal blood gas analysis.

Diagnostic Approach

History Taking

• Key Questions:
  • Duration of erection: Crucial for differentiating ischemic (typically >4 hours) from non-ischemic (can also be prolonged, but the urgency differs).
  • Pain level: Severe pain suggests ischemic; mild or no pain suggests non-ischemic.
  • Degree of rigidity: Fully rigid (ischemic) vs. partially rigid/spongy (non-ischemic).
  • Precipitating factors: Sexual stimulation? Trauma (perineal, penile)? Medication use (prescription, over-the-counter, recreational)? Intracavernosal injections?
  • Medical history: Sickle cell disease, other hematologic disorders, neurological conditions, cancer.
  • Prior episodes: History of stuttering priapism? Previous episodes of priapism?
  • Current medications: Detailed list of all drugs, especially those known to cause priapism (trazodone, alpha-blockers, PDE5 inhibitors, etc.).
• Red Flags:
  • Erection duration >4 hours: Immediate evaluation required.
  • Severe penile pain: Strong indicator of ischemic priapism, requires urgent intervention.
  • History of sickle cell disease: High risk for ischemic priapism.

Laboratory Tests

• First-Line:
  • Penile Corporal Blood Gas (PCBG): This is the most critical and definitive test to distinguish ischemic from non-ischemic priapism. A small amount (0.5-1 mL) of blood is aspirated from one of the corpora cavernosa (usually at the 10 or 2 o'clock position near the base of the penis) and immediately analyzed.
    • Ischemic Priapism: Classic findings are acidosis (pH <7.25), hypoxia (PO2 <30-40 mmHg), and hypercarbia (PCO2 >60 mmHg). The blood will appear dark, "venous."
    • Non-Ischemic Priapism: PCBG values will be similar to normal arterial blood gas (pH ~7.4, PO2 >90 mmHg, PCO2 ~40 mmHg). The blood will appear bright red, "arterial."
  • Complete Blood Count (CBC) with differential: To screen for underlying hematologic disorders (e.g., sickle cell trait/disease, leukemia, polycythemia).
  • Reticulocyte count, hemoglobin electrophoresis: If sickle cell disease is suspected or to confirm diagnosis in patients with priapism.
  • Toxicology screen: If illicit drug use is suspected.
• Confirmatory: PCBG is typically sufficient. Further labs are primarily for identifying underlying causes.
• Monitoring: No specific labs for monitoring acute priapism beyond resolution. For sickle cell patients, monitoring complete blood count, hydration status, and managing pain are essential.

Imaging

• Recommended:
  • Penile Doppler Ultrasound (PDUS): Should be performed if PCBG results are equivocal or if non-ischemic priapism is suspected.
    • Ischemic Priapism: Shows absent or markedly reduced cavernosal arterial flow (low velocity, high resistance). May demonstrate thrombus in the corpora.
    • Non-Ischemic Priapism: Shows normal or high cavernosal arterial flow (high velocity, low resistance) and often identifies the specific arteriovenous fistula (area of turbulent flow).
• Advanced:
  • Dynamic Cavernosography or Pelvic/Penile Angiography:
    • When needed: Primarily for localizing the arteriovenous fistula in non-ischemic priapism before selective arterial embolization. Also used if PDUS is inconclusive or for surgical planning.
  • MRI (Magnetic Resonance Imaging): Rarely used in acute priapism unless suspicion for tumor or complex trauma; may visualize corporal fibrosis in chronic cases. Not a first-line diagnostic tool.

Management

Acute Management

Key Principle: Ischemic priapism is a medical emergency. Time is corpora. Prompt intervention (<4-6 hours) is critical to preserve erectile function. Non-ischemic priapism is less urgent but still requires evaluation.

Ischemic Priapism (Emergency)

• Immediate (First-hour interventions):
  1. Analgesia: Administer systemic pain medication (e.g., IV opioids) to manage severe pain.
  2. Aspiration and Irrigation:
     • Technique: After penile block (dorsal penile nerve block with 1% lidocaine or direct cavernosal lidocaine infiltration) and sterile prep, aspirate 10-20 mL of blood from one corpus cavernosum using a large-bore needle (e.g., 16-18 gauge butterfly or spinal needle) at the 10 or 2 o'clock position at the base or mid-shaft. Repeat as needed, often changing to the contralateral corpus if aspiration is difficult or insufficient.
     • Purpose: Removes deoxygenated, acidotic blood, reducing intracorporal pressure and restoring some blood flow.
     • Irrigation: Irrigate the corpora with 10-20 mL aliquots of warm normal saline, repeating aspiration until bright red, oxygenated blood is seen, or detumescence occurs.
  3. Intracavernosal Alpha-Adrenergic Agonist Injection (Phenylephrine):
     • Preparation: Dilute phenylephrine to a concentration of 100-500 mcg/mL. A common method is 1 mL of 1% phenylephrine (10 mg) into 9 mL of normal saline to achieve 1 mg/mL, then taking 0.1-0.5 mL of this solution and diluting it further to the desired concentration or using direct injection based on the protocol. A common dose is 100-200 mcg injected every 5-10 minutes.
     • Maximum Dose: Total maximum dose should generally not exceed 1 mg in one hour (or 2-3 mg in 24 hours). Lower doses should be used in patients with cardiovascular risk factors.
     • Technique: Inject 100-200 mcg into the corpus cavernosum. Monitor blood pressure and heart rate closely.
     • Mechanism: Phenylephrine is an alpha-1 adrenergic agonist, causing smooth muscle contraction in the cavernosal sinusoids and penile arterioles, leading to venous outflow and arterial inflow reduction.
     • Contraindications: History of severe hypertension, severe coronary artery disease, recent MI, stroke, or concurrent use of MAO inhibitors.
     • Alternative (less common/available): Epinephrine (20 mcg/mL solution, 10-20 mcg every 5 min) or norepinephrine.
• Stabilization (Early management priorities):
  • Continue aspiration, irrigation, and phenylephrine injections for up to 1 hour, or until detumescence occurs.
  • If associated with sickle cell disease: Hydration, oxygenation, alkalinization (bicarbonate), and pain control are critical. Consider urgent exchange transfusion in consultation with hematology if conservative measures fail or in severe, prolonged cases to reduce sickle hemoglobin concentration.
• Emergency (Crisis management - Surgical Intervention):
  • If conservative measures fail (no detumescence after 1 hour of aspiration/irrigation/phenylephrine): Proceed to surgical shunting.
  • Types of Shunting:
    • Distal (corpora cavernosa to glans penis/corpus spongiosum) shunts:
      • Winter Shunt: Percutaneous creation of small windows between the corpus cavernosum and glans penis using a biopsy needle.
      • Al-Ghorab Shunt (Modified Winter): A larger incision is made in the glans, and a surgical punch creates a fenestration into the corpus cavernosum, followed by spatulation. Higher success rates than Winter shunt.
      • T-Shunt (corporoglanular): Incision at the distal glans, creating two small excisions of the tunica albuginea, then a dilator is used to create openings. Often combined with excisions of the distal corpora.
    • Proximal (corpora cavernosa to saphenous vein or corpus spongiosum) shunts: Less common, more invasive, generally reserved for failed distal shunts. Examples: Saphenous-cavernosal shunt (Quackels), Cavernosal-spongiosal shunt (Grayhack).
    • Timing: Shunting should be performed as soon as possible if conservative management fails, ideally within 24-36 hours of onset to maximize the chance of preserving erectile function.

Non-Ischemic Priapism

• Immediate:
  • Observation: Many cases of non-ischemic priapism, particularly those due to minor trauma, resolve spontaneously over hours to days/weeks. Initially, observation is often appropriate, especially if the erection is not rigid, painless, and the patient is stable. Ice packs to the perineum may be considered.
• Stabilization:
  • If persistent or bothersome to the patient, or if a definitive diagnosis of a fistula is made:
  • Selective Arterial Embolization: This is the first-line treatment for persistent non-ischemic priapism.
    • Procedure: Performed by an interventional radiologist. The pudendal artery and its branches are catheterized, and the arteriocavernosal fistula is identified and embolized using absorbable gelatin sponge (Gelfoam) particles or coils.
    • Advantages: Highly effective, minimally invasive, and can preserve future erectile function. Absorbable agents are preferred as they allow for revascularization and minimize risk of permanent ED.
• Emergency:
  • Surgical Ligation: If embolization fails or is not available, surgical exploration and ligation of the fistula may be necessary. This is more invasive and carries a higher risk of ED.

Chronic Management

• Recurrent (Stuttering) Priapism:
  • Pharmacological:
    • Acute episodes: Self-injection with a dilute alpha-agonist (e.g., phenylephrine) can be taught to patients for home use after initial training in the clinic.
    • Prophylactic/Preventative:
      • Oral PDE5 Inhibitors (e.g., sildenafil, tadalafil): Paradoxically, daily low-dose PDE5 inhibitors can prevent stuttering priapism by "resetting" smooth muscle tone and improving cGMP regulation.
      • Alpha-adrenergic agonists (e.g., pseudoephedrine, etilefrine): Oral agents can be used for prophylaxis by increasing sympathetic tone.
      • Antiandrogens (e.g., leuprolide, bicalutamide, finasteride): Can be considered in refractory cases by reducing nocturnal erections, but carry significant side effects.
      • Digoxin: Reported in some cases but not routinely recommended.
      • Hydroxyurea: Used in sickle cell patients to reduce sickling crises, which can indirectly reduce priapism episodes.
  • Non-pharmacological: Lifestyle modifications, avoiding triggers (if identified).
  • Monitoring: Regular follow-up to assess frequency and severity of episodes, medication side effects, and erectile function.

Treatment Algorithms

Algorithm for Priapism

1. Patient presents with persistent erection >4 hours.

   • Initial Assessment: History (duration, pain, rigidity, trauma, medications, medical history), Physical Exam (penile rigidity, glans involvement, pain).
   • Immediate Action: Obtain Penile Corporal Blood Gas (PCBG).

2. PCBG Results Differentiate:

   • A. Ischemic Priapism (Low-Flow)

     • PCBG: pH <7.25, PO2 <30-40 mmHg, PCO2 >60 mmHg (Dark blood).
     • Management within 1 hour:
       1. Analgesia (IV opioids).
       2. Penile Aspiration and Irrigation (with normal saline).
       3. Intracavernosal Phenylephrine Injection (100-200 mcg every 5-10 min, max 1 mg/hr).
       4. Sickle Cell Patients: Hydration, oxygen, alkalinization, pain control, hematology consult (consider exchange transfusion).
     • Response to Initial Treatment?
       • YES (Detumescence): Observe.
       • NO (No detumescence after 1 hour): Proceed to Surgical Shunting (Distal shunts, e.g., T-shunt/Al-Ghorab, preferred first).
         • If distal shunt fails: Consider Proximal Shunt.

   • B. Non-Ischemic Priapism (High-Flow)

     • PCBG: pH ~7.4, PO2 >90 mmHg, PCO2 ~40 mmHg (Bright red blood).
     • Confirm with Penile Doppler Ultrasound: Detects normal/high flow and arteriovenous fistula.
     • Management:
       1. Observation: Initially, many resolve spontaneously. Ice packs.
       2. If persistent/bothersome: Selective Arterial Embolization (first-line).
       3. If embolization fails or unavailable: Surgical Ligation of fistula.

Algorithm for Recurrent (Stuttering) Priapism

1. Diagnosis: History of recurrent, self-limiting painful erections.
2. Acute Episode Management:
   • Oral analgesics.
   • Oral alpha-agonists (e.g., pseudoephedrine).
   • Patient education on self-management and when to seek urgent care if an episode becomes prolonged (>4 hours).
   • Consider teaching patients intracavernosal phenylephrine self-injection for acute episodes (after training).
3. Prophylactic Management (Daily/Regular):
   • First-Line: Oral PDE5 inhibitors (daily low dose, e.g., tadalafil 5 mg daily).
   • Second-Line: Oral alpha-agonists (e.g., pseudoephedrine), or antiandrogens (e.g., finasteride, leuprolide).
   • Sickle Cell Disease: Hydroxyurea (primary treatment for SCD) is effective for reducing priapism episodes.

Complications

• Common:
  • Erectile Dysfunction (ED): The most frequent and feared complication, especially with ischemic priapism. The risk significantly increases with longer duration of ischemia (e.g., >24-36 hours).
  • Penile fibrosis: Resulting from ischemic damage and subsequent scarring.
• Serious:
  • Penile necrosis and gangrene (rare, in prolonged, untreated ischemic priapism).
  • Urinary retention (due to pain or penile swelling).
  • Infection (post-procedure).
• Long-term:
  • Persistent ED, often requiring penile prosthesis implantation.
  • Penile deformity (curvature, shortening) due to fibrosis.
  • Psychological distress, anxiety, depression related to sexual function.

Prognosis

• Factors Affecting Outcome:
  • Duration of Ischemia: The single most important prognostic factor for erectile function.
    • <12 hours: ED risk approximately 10-20%.
    • 12-24 hours: ED risk approximately 50%.

    • 36 hours: ED risk >90%.

    • The longer the duration, the greater the likelihood of irreversible corporal smooth muscle damage and fibrosis.
  • Etiology: Priapism secondary to sickle cell disease tends to have a higher recurrence rate and often a poorer long-term prognosis for ED compared to idiopathic cases, even with timely intervention.
  • Type of Priapism: Non-ischemic priapism generally has an excellent prognosis for preserved erectile function, especially with selective arterial embolization using absorbable materials.
  • Timeliness and Efficacy of Treatment: Prompt and effective detumescence is crucial.
• Survival: Priapism itself is rarely life-threatening, but underlying conditions (e.g., leukemia, severe sickle cell crisis) can affect overall survival.
• Quality of Life: Significantly impacted by long-term ED, penile deformity, and the psychological burden of the condition. Many patients with severe ED secondary to priapism eventually opt for penile prosthesis implantation.

Prevention

• Primary (Preventing initial occurrence):
  • Careful Medication Use: Avoid recreational drugs. For patients on medications known to cause priapism (e.g., trazodone, alpha-blockers), awareness and prompt action if an erection persists are important. Discuss risks with patients prescribed intracavernosal injections or high-dose PDE5 inhibitors.
  • Management of Underlying Conditions: Optimal management of sickle cell disease (e.g., hydroxyurea therapy) significantly reduces the incidence of priapism episodes.
• Secondary (Early detection and intervention):
  • Patient Education: Educate patients (especially those at high risk, e.g., sickle cell patients, those using intracavernosal injections) about the definition of priapism, its symptoms, the 4-hour rule, and the importance of seeking immediate medical attention. Provide clear instructions on what to do.
  • For stuttering priapism: Prompt use of rescue oral medications (e.g., pseudoephedrine) or self-injected phenylephrine (if trained) to prevent progression to full ischemic priapism.
• Tertiary (Preventing complications):
  • Timely and Aggressive Treatment: Adherence to treatment algorithms to achieve detumescence as quickly as possible.
  • Follow-up and Rehabilitation: Post-priapism follow-up for assessment of erectile function and management of ED (e.g., oral ED meds, vacuum erection devices, penile prosthesis if needed).

Special Populations

• Pediatric:
  • Etiology: Sickle cell disease is the most common cause of priapism in children. Leukemia can also be a cause.
  • Management: Initial management follows adult guidelines (aspiration, phenylephrine). Analgesia and anxiolysis are crucial. In sickle cell patients, aggressive management of the sickle cell crisis (hydration, oxygenation, pain control, consider exchange transfusion) is paramount. Surgical shunting is performed if conservative measures fail. Special considerations for long-term psychological impact and future sexual health.
• Geriatric:
  • Etiology: More likely to be medication-induced (e.g., alpha-blockers for BPH, antidepressants, PDE5 inhibitors). Higher prevalence of comorbidities (cardiovascular disease, hypertension, diabetes).
  • Management: Closer monitoring of blood pressure and heart rate during phenylephrine injection due to increased cardiovascular risk. Careful consideration of drug interactions.
• Pregnancy: Priapism does not directly affect pregnant individuals, but if a male partner develops priapism, it should be managed as usual. No direct implications for pregnancy outcomes.
• Comorbidities:
  • Sickle Cell Disease: Requires a multidisciplinary approach involving urology and hematology. Aggressive management of the underlying sickle cell crisis (hydration, oxygen, pain control, exchange transfusion) is crucial alongside local penile interventions. Hydroxyurea is a primary preventative measure.
  • Cardiovascular Disease/Hypertension: Use phenylephrine with extreme caution; monitor vital signs closely. Lower initial doses and slower titration may be warranted.
  • Leukemia: Consider leukapheresis in addition to local measures if very high white blood cell counts are contributing to hyperviscosity and sludging.

Clinical Pearls

• Diagnostic:
  • "Time is corpora": Always assume ischemic priapism until proven otherwise. The 4-hour mark is critical for intervention.
  • PCBG is paramount: Do not delay obtaining a penile corporal blood gas. It is the quickest and most accurate way to differentiate ischemic from non-ischemic priapism. Physical exam alone is unreliable for this distinction.
  • Glans flaccidity: A rigid shaft but soft glans is a classic sign of ischemic priapism; this differentiates it from a normal erection or high-flow priapism, where the glans may also be engorged.
• Treatment:
  • Ischemic Priapism:
    • Start with aspiration and irrigation: This immediately reduces pressure and removes toxic blood, even before phenylephrine.
    • Phenylephrine dosage: Start low (100-200 mcg) and titrate up, ensuring close cardiovascular monitoring.
    • Do not delay surgery: If conservative measures fail after 1 hour, proceed directly to surgical shunting. Waiting longer significantly increases ED risk.
  • Non-Ischemic Priapism:
    • Observation first: Many cases resolve spontaneously.
    • Embolization is preferred: Selective arterial embolization with absorbable agents is the treatment of choice, as it preserves future erectile function.
• Pitfalls:
  • Delay in seeking care: Patients often delay presentation due to embarrassment, leading to worse outcomes. Education is key.
  • Misdiagnosis: Confusing ischemic priapism with a normal erection or non-ischemic priapism due to inadequate diagnostic workup (e.g., not performing PCBG).
  • Inadequate phenylephrine dosage/frequency: Not using enough or not repeating injections frequently enough can lead to failed medical management.
  • Over-reliance on conservative measures: Persisting with aspiration/injection beyond the recommended timeframe (e.g., >1 hour) for ischemic priapism when surgical shunting is indicated.
  • Ignoring underlying causes: Failing to investigate and manage conditions like sickle cell disease, which can lead to recurrent episodes.

Recent Updates

• Guidelines: The American Urological Association (AUA) and European Association of Urology (EAU) regularly update their guidelines on priapism. Current guidelines continue to emphasize prompt diagnosis using PCBG and aggressive early intervention for ischemic priapism.
• Evidence:
  • Increasing evidence supports the role of oral PDE5 inhibitors and alpha-agonists as prophylactic agents for recurrent (stuttering) priapism, particularly in sickle cell patients.
  • Ongoing research is exploring novel targets for ischemic priapism, including adenosine A2B receptor antagonists, endothelin receptor antagonists, and gene therapy approaches, though these are not yet standard clinical practice.
  • Improvements in embolization techniques and materials for non-ischemic priapism have further cemented its role as the first-line treatment.
• Controversies:
  • Optimal timing and specific type of surgical shunts in refractory cases.
  • The exact role and efficacy of different prophylactic regimens for stuttering priapism, especially in non-sickle cell patients.
  • The utility of exchange transfusion in all cases of sickle cell priapism vs. selective use based on severity and response to initial measures.

Key References

• Guidelines:
  • American Urological Association (AUA) Guideline: Priapism. Latest version should be consulted (e.g., updated 2021 or subsequent).
  • European Association of Urology (EAU) Guidelines: Urological Emergencies, including priapism. Latest version.
• Studies:
  • Ezeh U, et al. Management of priapism: a systematic review. J Urol. 2013;189(6):2189-2196. (Though older, provides foundational review).
  • Broderick GA, et al. Priapism: the AUA guideline on the management of priapism. J Urol. 2018;200(5):1108-1115. (Key reference for US practice).
  • Burnett AL, et al. Sickle Cell Disease and Priapism: Management and Prevention. Sex Med Rev. 2020;8(3):399-410.
• Reviews:
  • Yuan J, et al. The aetiology, diagnosis and treatment of priapism: an updated review. Asian J Androl. 2016;18(1):15-23.
  • Podolej GS, et al. Emergency department management of priapism. Emerg Med Pract. 2018;20(10):1-20.